Ann: Remestemcel-L for COVID-19 MIS-C published in Pediatrics, page-79

Novartis DD time is up in the next 48 hours.


I actually don’t think that is the case ? ... the original announcement of the collaboration was -


Melbourne, Australia; November 20, and New York, USA; November 19, 2020: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), today announced that it has entered into an exclusive worldwide license and collaboration agreement with Novartis for the development, manufacture and commercialization of Mesoblast’s mesenchymal stromal cell (MSC) product remestemcel-L, with an initial focus on the development of the treatment of acute respiratory distress syndrome (ARDS), including that associated with COVID-19.


So 30 days for the original deal was up on or about 20th December, 2020 .... right about the same time Novartis advised the media it had requested a 90 day extension .....


https://endpts.com/novartis-partnered-stem-cell-therapy-flunks-phiii-trial-in-covid-19/


So wouldn’t the 90 day ‘extension’ start from on or about the 19th December 2020 making the 19th March, 2021 the actual new cut off date ? .... I mean if I owed you $5,000 and it was due on the 19th December, 2020 and I requested a 90 day extension I know I wouldn’t expect to have to pay you until the 19th March, 2021. (+90 days)


“extension” by definition is a part that is added to something to enlarge or prolong it.

This 19th March, 2021 date makes sense to me as it would give Novartis time to assess the COVID-19 ARDS data thoroughly as they probably won’t even receive the raw data until next week ? (IMO of course)